Menu

In Failing Hearts, Cardiomyocytes Alter Metabolism

While the heart cells normally burn fatty acids, when things go wrong ketones become the preferred fuel source.

Jun 1, 2016
Amanda B. Keener

CHANGE-UP: Healthy cardiomyocytes (left panel) mainly use fatty acids as their energy source. But in a mouse model of heart failure and in failing human hearts (right panel), cardiomyocytes depend more on ketones for energy. 
See full infographic: WEB
THE SCIENTIST STAFF

EDITOR'S CHOICE IN CELL & MOLECULAR BIOLOGY

The paper
G. Aubert et al., “The failing heart relies on ketone bodies as a fuel,” Circulation, 133:698-705, 2016.

As organs go, the heart is an energy hog. To keep it fueled, mitochondria within cardiomyocytes (heart muscle cells) constantly churn out ATP as a product of the citric acid cycle. In the heart, most of the cycle’s substrates come from the metabolism of fatty acids, but the organ can also make use of other compounds such as lactate or ketones.

When Daniel Kelly of Sanford Burnham Prebys Medical Discovery Institute in Orlando, Florida, learned that some rare genetic disorders both cause dysfunction of the heart muscle and simultaneously disrupt fatty acid oxidation and increase ketone metabolism, he wondered if ketones might play a role in heart failure. “It was kind of a genetic proof of concept that these fuel changes might really be important, rather than just innocent bystanders,” he says.

During starvation, the liver makes extra ketones, allowing the brain to switch to ketones for fuel when glucose is low. To find out whether a similar process occurs early in heart failure, Kelly’s team mimicked two common causes of human heart failure—heart attack and hypertension caused by aorta constriction—in mice, and performed proteomic analyses four weeks later.

They observed lowered levels of proteins that process fatty acids for energy and increased levels of a ketone-metabolizing enzyme called βOHB dehydrogenase 1 (BDH1). They also found elevated levels of three ketone metabolites, and when the team perfused excised hearts with a radioactively labeled version of the ketone βOHB, hypertrophied hearts ate up more of the ketone to produce substrates for the citric acid cycle than healthy hearts did.

Kenneth Margulies and colleagues at the University of Pennsylvania saw similar metabolic changes in failing human hearts sampled during surgery or removed during cardiac transplantation (Circulation, 133:706-16, 2016). Margulies’s team observed that the expression of the genes for BDH1 and other ketone-metabolizing enzymes ramped up in failing heart tissue. Although failing hearts and healthy controls (from organ donors) displayed no differences in the abundance of proteins involved in fatty acid oxidation, failing ones had lower levels of fatty acid intermediates called acylcarnitines, suggesting the hearts were not using their normal fuel source.

Both mice and humans with heart failure had increased concentrations of ketones in their serum, hinting that ketone production in the liver was increased. “This was really fascinating because that means there is a liver-heart connection,” Kelly says. To find out if that’s the case, he plans to study mice lacking an enzyme required for ketone production in the liver.

These mice will also be useful in discerning whether the switch to ketones is a good thing. “We don’t know if it’s adaptation or maladaptation,” says Heinrich Taegtmeyer, a cardiologist at the University of Texas Health Science Center in Houston. Figuring that out could potentially inform ways to protect hearts in bad situations.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.